JP4411472B2 - エリスロポエチン受容体結合抗体 - Google Patents

エリスロポエチン受容体結合抗体 Download PDF

Info

Publication number
JP4411472B2
JP4411472B2 JP2004544846A JP2004544846A JP4411472B2 JP 4411472 B2 JP4411472 B2 JP 4411472B2 JP 2004544846 A JP2004544846 A JP 2004544846A JP 2004544846 A JP2004544846 A JP 2004544846A JP 4411472 B2 JP4411472 B2 JP 4411472B2
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
acid sequence
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004544846A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006523083A5 (de
JP2006523083A (ja
Inventor
デブリーズ，ピーター・ジエイ
グリーン，ラリー・エル
オストロウ，デイビツド・エイチ
ライリー，エドワード・ビー
ウイーラー，ジエイムズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/269,711 external-priority patent/US20040071694A1/en
Priority claimed from US10/684,109 external-priority patent/US7396913B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of JP2006523083A publication Critical patent/JP2006523083A/ja
Publication of JP2006523083A5 publication Critical patent/JP2006523083A5/ja
Application granted granted Critical
Publication of JP4411472B2 publication Critical patent/JP4411472B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2004544846A 2002-10-14 2003-10-14 エリスロポエチン受容体結合抗体 Expired - Fee Related JP4411472B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/269,711 US20040071694A1 (en) 2002-10-14 2002-10-14 Erythropoietin receptor binding antibodies
US10/684,109 US7396913B2 (en) 2002-10-14 2003-10-10 Erythropoietin receptor binding antibodies
PCT/US2003/032243 WO2004035603A2 (en) 2002-10-14 2003-10-14 Erythropoietin receptor binding antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009029449A Division JP2009149665A (ja) 2002-10-14 2009-02-12 エリスロポエチン受容体結合抗体

Publications (3)

Publication Number Publication Date
JP2006523083A JP2006523083A (ja) 2006-10-12
JP2006523083A5 JP2006523083A5 (de) 2009-04-02
JP4411472B2 true JP4411472B2 (ja) 2010-02-10

Family

ID=32109805

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004544846A Expired - Fee Related JP4411472B2 (ja) 2002-10-14 2003-10-14 エリスロポエチン受容体結合抗体
JP2009029449A Pending JP2009149665A (ja) 2002-10-14 2009-02-12 エリスロポエチン受容体結合抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009029449A Pending JP2009149665A (ja) 2002-10-14 2009-02-12 エリスロポエチン受容体結合抗体

Country Status (13)

Country Link
EP (1) EP1578779A4 (de)
JP (2) JP4411472B2 (de)
KR (1) KR20050059263A (de)
CN (1) CN103524618A (de)
AU (2) AU2003282588B2 (de)
BR (1) BR0315275A (de)
CA (1) CA2501984C (de)
MX (1) MXPA05003997A (de)
NZ (1) NZ539263A (de)
PL (1) PL379985A1 (de)
TW (1) TWI320716B (de)
WO (1) WO2004035603A2 (de)
ZA (1) ZA201004902B (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2363404B8 (de) * 2001-10-23 2016-12-07 PSMA Development Company L.L.C. PSMA Antikörper
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2006121422A2 (en) * 2004-02-06 2006-11-16 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof
US20050227289A1 (en) * 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
CA2701032C (en) 2007-09-27 2021-01-26 Amgen Inc. Pharmaceutical formulations
EP3381445B1 (de) 2007-11-15 2023-10-25 Amgen Inc. Wässrige antikörperformulierung mit stabilisierung durch antioxidantien zur parenteralen verabreichung
JP5701064B2 (ja) 2008-01-25 2015-04-15 アムジエン・インコーポレーテツド フェロポーチン抗体およびその使用方法
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
JP2012500818A (ja) * 2008-08-28 2012-01-12 エフ．ホフマン−ラ ロシュ アーゲー ヒトｅｐｏ受容体に対する抗体
CA3019967A1 (en) 2008-11-13 2010-05-20 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation of bmp-6
CA2965031C (en) 2009-01-15 2018-12-04 F. Hoffmann-La Roche Ag Antibodies against phosphorylated tyrosines on erythropoietin receptor (epor)
EP2490957B1 (de) 2009-10-23 2016-11-23 Amgen, Inc Fläschchenadapter und system damit
RS54291B2 (sr) 2010-06-07 2023-12-29 Amgen Inc Uređaj za isporuku lekova
US9480624B2 (en) 2011-03-31 2016-11-01 Amgen Inc. Vial adapter and system
CA3021845C (en) 2011-04-20 2022-03-29 Amgen Inc. Autoinjector apparatus
MY166974A (en) 2011-06-15 2018-07-27 Hoffmann La Roche Anti-human epo receptor antibodies and method of use
IL308846B2 (en) 2011-10-14 2025-03-01 Amgen Inc Injector and assembly method
EP3081249B1 (de) 2012-11-21 2020-12-30 Amgen Inc. Arzneimittelabgabevorrichtung
TWI580451B (zh) 2013-03-15 2017-05-01 安美基公司 用於注射器之匣盒及使用具有自動注射器及匣盒之自動注射器設備之方法
TWI639449B (zh) 2013-03-15 2018-11-01 美商安美基公司 用於注射器之匣盒
TWI592183B (zh) 2013-03-15 2017-07-21 安美基公司 本體輪廓可調適之自動注射器裝置
AU2014236677B2 (en) 2013-03-15 2018-07-05 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
KR102287687B1 (ko) 2013-03-22 2021-08-06 암젠 인크 인젝터 및 조립 방법
US10758683B2 (en) 2013-10-24 2020-09-01 Amgen Inc. Drug delivery system with temperature-sensitive control
EP3789064B1 (de) 2013-10-24 2024-11-27 Amgen Inc. Injektor und verfahren zur montage
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
CA2945026C (en) 2014-05-07 2023-10-10 Amgen Inc. Autoinjector with shock reducing elements
EP4362039A3 (de) 2014-06-03 2024-08-07 Amgen Inc. Steuerbares arzneimittelabgabesystem und verfahren zur verwendung
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
MX2021014323A (es) 2014-10-14 2023-02-02 Amgen Inc Dispositivo de inyección de fármaco con indicadores visuales y audibles.
ES2785311T3 (es) 2014-12-19 2020-10-06 Amgen Inc Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
ES2898469T3 (es) 2014-12-19 2022-03-07 Amgen Inc Dispositivo de administración de medicamentos con sensor de proximidad
CA2976935C (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3981450A1 (de) 2015-02-27 2022-04-13 Amgen, Inc Arzneimittelabgabevorrichtung mit nadelschutzmechanismus mit abstimmbarem widerstandsschwellwert gegenüber der bewegung des nadelschutzes
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
ES2755717T3 (es) 2015-12-09 2020-04-23 Amgen Inc Autoinyector con tapa de señalización
CN105542006A (zh) * 2015-12-11 2016-05-04 北京大学第一医院 抗epor融合蛋白抗体的制备方法和用途
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
EP4035711B1 (de) 2016-03-15 2025-06-04 Amgen Inc. Verringerung der wahrscheinlichkeit auf glasbruch in arzneimittelabgabevorrichtungen
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
ES2959783T3 (es) 2016-05-13 2024-02-28 Amgen Inc Conjunto de cubierta protectora de vial
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
EP3465124A1 (de) 2016-06-03 2019-04-10 Amgen Inc. Wirkungstestvorrichtungen und verfahren für wirkstofffreisetzungsvorrichtungen
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
EP3532127A1 (de) 2016-10-25 2019-09-04 Amgen Inc. Injektor am körper
US20190358411A1 (en) 2017-01-17 2019-11-28 Amgen Inc. Injection devices and related methods of use and assembly
CA3052204A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
JP7064501B2 (ja) 2017-02-17 2022-05-10 アムジエン・インコーポレーテツド 無菌流体流路を備える薬物送達デバイスおよび関連する組立方法
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
IL268478B2 (en) 2017-03-07 2023-10-01 Amgen Inc Inserting a needle using super pressure
CA3052310A1 (en) 2017-03-09 2018-09-13 Amgen Inc. Insertion mechanism for drug delivery device
EP3570871B1 (de) 2017-03-20 2020-11-18 H. Hoffnabb-La Roche Ag Verfahren für in-vitro-glyco-engineering eines erythropoiesestimulierenden proteins
HUE063805T2 (hu) 2017-03-28 2024-01-28 Amgen Inc Dugattyúrúd és fecskendõ összeállító rendszer és eljárás
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
MX2019014615A (es) 2017-06-08 2020-02-07 Amgen Inc Dispositivo de administracion de farmacos accionado por par de torsion.
EP3641857A1 (de) 2017-06-22 2020-04-29 Amgen Inc. Aufprall-/stossdämpfungsminderung bei geräteaktivierung
AU2018290302B2 (en) 2017-06-23 2024-02-29 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
ES2972207T3 (es) 2017-07-14 2024-06-11 Amgen Inc Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble
JP7649105B2 (ja) 2017-07-21 2025-03-19 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
US11617837B2 (en) 2017-07-25 2023-04-04 Amgen Inc. Drug delivery device with gear module and related method of assembly
MA49676A (fr) 2017-07-25 2020-06-03 Amgen Inc Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
US11759565B2 (en) 2017-10-04 2023-09-19 Amgen Inc. Flow adapter for drug delivery device
EP3691716B1 (de) 2017-10-06 2023-11-29 Amgen Inc. Arzneimittelabgabevorrichtung mit verriegelungsvorrichtung und zugehöriges montageverfahren
EP3694578B1 (de) 2017-10-09 2025-09-24 Amgen Inc. Arzneimittelabgabevorrichtung mit antriebsanordnung sowie zugehöriges verfahren zur montage
MA50528A (fr) 2017-11-03 2020-09-09 Amgen Inc Systèmes et approches pour stériliser un dispositif d'administration de médicament
EP3707075A1 (de) 2017-11-06 2020-09-16 Amgen Inc. Füllabschlussanordnungen und zugehörige verfahren
MA50553A (fr) 2017-11-06 2020-09-16 Amgen Inc Dispositif d'administration de médicament avec détection de positionnement et de débit
MX2020004736A (es) 2017-11-10 2020-08-13 Amgen Inc Embolos para dispositivos de administracion de farmacos.
WO2019099324A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
SG11202002772VA (en) 2017-11-16 2020-04-29 Amgen Inc Autoinjector with stall and end point detection
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
CN112469454B (zh) 2018-07-24 2024-01-26 安进公司 用于施用药物的输送装置
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
MA53375A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
US12109389B2 (en) 2018-07-31 2024-10-08 Amgen Inc. Fluid path assembly for a drug delivery device
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
EP3856283A1 (de) 2018-09-28 2021-08-04 Amgen Inc. Anordnung zur aktivierung des muskeldrahtvorschubs für eine medikamentenabgabevorrichtung
WO2020072577A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
EP3860686A1 (de) 2018-10-05 2021-08-11 Amgen Inc. Medikamentenabgabevorrichtung mit dosisindikator
AR116703A1 (es) 2018-10-15 2021-06-02 Amgen Inc Proceso de ensamblaje de plataforma para un dispositivo de administración de fármacos
EA202191037A1 (ru) 2018-10-15 2021-08-05 Эмджен Инк. Устройство доставки лекарственного средства, имеющее демпферный механизм
IL281908B2 (en) 2018-11-01 2025-06-01 Amgen Inc Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
MA54048A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
KR20210121045A (ko) * 2018-12-27 2021-10-07 기가젠, 인코포레이티드 항-ctla-4 결합 단백질 및 이의 사용 방법
MX2021012557A (es) 2019-04-24 2021-11-12 Amgen Inc Conjuntos y metodos de verificacion de esterilizacion de jeringuillas.
CA3148261A1 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
EP4341161A1 (de) 2021-05-21 2024-03-27 Amgen Inc. Verfahren zur optimierung eines füllrezepts für einen arzneimittelbehälter
IL319976A (en) 2022-11-02 2025-05-01 Hoffmann La Roche Method for producing glycoprotein compositions
CN119080938B (zh) * 2023-06-05 2025-06-24 东莞市朋志生物科技有限公司 抗25羟维生素d抗体、检测25羟维生素d的试剂和试剂盒
CN120365421B (zh) * 2025-04-24 2025-11-04 成都古格尔生物技术有限公司 一种特异性抗sez6靶点的全人源抗体及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008822A1 (en) * 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
AU6163196A (en) * 1995-06-07 1996-12-30 Smithkline Beecham Corporation Method for obtaining receptor agonist antibodies
AU3492497A (en) * 1996-06-21 1998-01-07 Arris Pharmaceutical Corporation Bivalent molecules that form an activating complex with an erythropoietin receptor
US6103879A (en) * 1996-06-21 2000-08-15 Axys Pharmaceuticals, Inc. Bivalent molecules that form an activating complex with an erythropoietin receptor
JP2002544123A (ja) * 1999-04-14 2002-12-24 スミスクライン・ビーチャム・コーポレイション エリトロポイエチン受容体抗体

Also Published As

Publication number Publication date
AU2010214778A1 (en) 2010-09-23
CA2501984C (en) 2011-04-26
CN103524618A (zh) 2014-01-22
BR0315275A (pt) 2005-08-30
CA2501984A1 (en) 2004-04-29
PL379985A1 (pl) 2006-11-27
AU2003282588A1 (en) 2004-05-04
EP1578779A4 (de) 2011-11-16
KR20050059263A (ko) 2005-06-17
EP1578779A2 (de) 2005-09-28
ZA201004902B (en) 2012-06-27
WO2004035603A2 (en) 2004-04-29
MXPA05003997A (es) 2005-06-22
JP2009149665A (ja) 2009-07-09
JP2006523083A (ja) 2006-10-12
TWI320716B (en) 2010-02-21
AU2003282588B2 (en) 2010-06-03
WO2004035603A3 (en) 2006-04-27
NZ539263A (en) 2009-07-31
TW200418505A (en) 2004-10-01

Similar Documents

Publication Publication Date Title
JP4411472B2 (ja) エリスロポエチン受容体結合抗体
US7396913B2 (en) Erythropoietin receptor binding antibodies
TWI866043B (zh) 細胞毒性t淋巴球相關蛋白4(ctla-4)之新穎單株抗體
EP1732950B1 (de) Antikörper gegen den erythropoietinrezeptor und verwendungen davon
CN110366560B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
CA2932966C (en) Pd-1 antibody, antigen-binding fragment thereof, and medical use thereof
CN101027322B (zh) 促红细胞生成素受体结合抗体
CA2479927A1 (en) Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
AU2019208793A1 (en) Anti-4-1BB antibody, antigen-binding fragment thereof and medical use thereof
CN114437227A (zh) 双特异抗体及其应用
JP7297090B2 (ja) ＰＤＬ１及びＴＧＦβに対する二機能性融合タンパク質並びにその使用
WO2023036281A1 (zh) 抗cd47抗体及其用途
JP2025503772A (ja) 抗ｂ７－ｈ７抗体もしくはその抗原結合断片及び製造方法と応用
US20060018902A1 (en) Antibodies to erythropoietin receptor and uses thereof
CN115925917A (zh) 抗pvrig蛋白抗体或抗体片段及其用途
CN121079322A (zh) 抗cd27单克隆抗体及其应用
KR20220110522A (ko) 항gdf15 항체
CN115947855B (zh) 抗cd24抗体的制备及其用途
CN115521379B (zh) Pd-1抗体及其用途
KR20260008771A (ko) 항-cd40l 항체와 인간 자가면역 질환 치료에서의 그 용도
HK40073393A (en) Bispecific antibody and use thereof
CN116478288A (zh) 红细胞弱结合型人源化cd47抗体及其应用
HK1103746B (en) Antibodies to erythropoietin receptor and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090212

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090603

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090908

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091013

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20090930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091030

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121127

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees